KYTX Kyverna Therapeutics
- 15.500
- +0.870+5.95%
Kyverna Therapeutics News
Kyverna Therapeutics | 10-Q: Quarterly report
Express News | Kyverna Therapeutics Q1 2024 Adj EPS $(1.12) Misses $(0.84) Estimate
Express News | Kyverna Therapeutics Inc: Qtrly Shr Loss $1.12
Express News | Kyverna Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
8 Out of 12 S&P 500 Healthcare Companies Beat Profit Consensus This Week: Earnings Scorecard
Why Clever Leaves Holdings Shares Are Trading Lower By Around 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Clever Leaves Holdings Inc. (NASDAQ:CLVR) fell sharply during Monday's session after the company announced that it will voluntarily delist its common shares from the Nasdaq and deregister it
Express News | Kyverna Therapeutics To Attend The 2024 AAN Annual Meeting With Data On KYV-101 In Treatment Of Patients With Neurological Autoimmune Diseases
Kyverna Therapeutics to Attend the 2024 American Academy of Neurology (AAN) Annual Meeting in Denver, CO, With Data on KYV-101 in the Treatment of Patients With Neurological Autoimmune Diseases
Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for...
12 Health Care Stocks Moving In Monday's After-Market Session
GainersOpGen (NASDAQ:OPGN) shares moved upwards by 24.0% to $0.74 during Monday's after-market session. The market value of their outstanding shares is at $7.4 million. Galecto (NASDAQ:GLTO) shares in
First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patients With Progressive Multiple Sclerosis Published in Med
Two patients were treated with KYV-101, a fully human anti-CD19 CAR T-cell product candidate, in Germany as part of a named patient program after failure to respond to conventional therapies The trea
Kyverna Therapeutics FY23 EPS $(89.61) Vs $(63.43) YoY
Financial Results for the Year Ended December 31, 2023For the year ended December 31, 2023, the company reported a net loss of $60.4 million, or a net loss per common share of $89.61, compared to a ne
Kyverna Therapeutics 2023 R&D Expenses $49.9M >KYTX
Kyverna Therapeutics 2023 R&D Expenses $49.9M >KYTX
Press Release: Kyverna Therapeutics Provides Business Update and Reports Full Year 2023 Financial Results
Kyverna Therapeutics Provides Business Update and Reports Full Year 2023 Financial Results PR Newswire EMERYVILLE, Calif., March 26, 2024 -- Advanced clinical development in two broad areas of a
Heard on the Street: Why That Hot Biotech IPO Could Be a Winner -- WSJ
By David Wainer The best time to make money in biotech is usually during periods of cautious optimism. There are strong signs that right now might be one of those moments. The always-volatile indust
Sector Update: Health Care Stocks Steady Pre-Bell Friday
Health care stocks were steady pre-bell Friday as the iShares Biotechnology ETF (IBB) was inactive and the Health Care Select Sector SPDR Fund (XLV) was up a slight 0.1% recently. Amylyx Pharmaceutica
Kyverna Therapeutics And Stanford University Collaborate To Evaluate KYV-101 In Patients With Non-Relapsing And Progressive Forms Of Multiple Sclerosis
The Investigator-Initiated Trial will assess the safety, tolerability, and clinical activity of KYV-101, a fully human anti CD19 CAR T-cell therapy in up to 12 study participantsThe clinical study wil
Kyverna Therapeutics and Stanford University Agree to Evaluate KYV-101 in Patients With Non-Relapsing and Progressive Forms of Multiple Sclerosis
Kyverna Therapeutics, Inc. (Kyverna), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients...
How Kyverna Is Positioned for Success on Autoimmune Therapy: CEO
Kyverna Therapeutics Price Target Announced at $39.00/Share by JP Morgan
Kyverna Therapeutics Price Target Announced at $39.00/Share by JP Morgan
Kyverna Therapeutics Initiated at Overweight by Morgan Stanley
Kyverna Therapeutics Initiated at Overweight by Morgan Stanley
Analysis
Price Target
No Data
